AI Tool Comparison
Comparing as AI Remote Patient MonitoringCurrent Health vs Biofourmis
Current Health
VS
Biofourmis
Verdict by Category
Detailed Comparison
Feature
Current Health
Biofourmis
Pricing
EnterpriseCurrent Health is an enterprise-only platform with no public pricing. All deployments are custom contracts negotiated directly with health systems, payers, and home health agencies.
Pricing is based on patient volume, care program type (Hospital@Home, chronic care management, post-acute monitoring), integration requirements, and the level of Clinical Command Center support required.
Contact Current Health through currenthealth.com to request a demo and enterprise pricing discussion.
EnterpriseBiofourmis is an enterprise-only platform with no public pricing. All contracts are custom, negotiated directly with health systems, IDNs, hospitals, and payers.
Pricing is based on patient volume, care program type (Hospital@Home, chronic disease management, post-acute care), integration requirements, and contract term. The platform is typically deployed under value-based care arrangements where costs are linked to patient outcomes and readmission reduction.
Contact Biofourmis through biofourmis.com to request a demo and enterprise pricing discussion.
Categories
AI Healthcare ToolsAI Productivity Tools
AI Healthcare ToolsAI Research & Education Tools
Summary
Enterprise care-at-home platform — FDA-cleared wearable monitoring, telehealth, and clinical command center
AI remote patient monitoring with 120+ biomarkers — Hospital@Home and predictive care delivery
Current Health Pros & Cons
Pros
- FDA-cleared wearable delivers ICU-level vital sign accuracy at home — highest clinical standard in consumer RPM
- Acquired by Best Buy (2021) — enterprise-scale logistics, retail distribution, and commercial backing
- Trusted by Mount Sinai, Geisinger, Mayo Clinic, UK NHS, and AstraZeneca — proven at top-tier health systems
- All-in-one platform: RPM + telehealth + patient engagement + command center in single solution
- 24/7 Clinical Command Center reduces provider burden — offloads monitoring operations from health system staff
- Customizable clinical algorithms per patient — reduces false alarms and focuses alerts on clinically meaningful signals
- Revenues grew 3,000% YoY in 2020 — proven market demand and real-world scalability
Cons
- Enterprise-only platform — not available for individual clinicians or small practices
- Requires Best Buy Health partnership for full deployment — limits flexibility for some health systems
- No public pricing — evaluation requires direct sales engagement
- Device-dependent model — requires wearable distribution logistics and patient onboarding
- Primarily focused on US and UK markets
- Competition from Biofourmis, Teladoc, and other RPM platforms with similar hospital-at-home capabilities
Biofourmis Pros & Cons
Pros
- FDA 510(k) cleared + FDA Breakthrough Device Designation for BiovitalsHF — highest regulatory validation in RPM
- $461.85M raised, $1.3B unicorn valuation — General Atlantic, CVS Health, SoftBank Vision Fund 2 backing
- 120+ biomarker real-time analysis — most comprehensive predictive RPM analytics platform available
- Proven clinical outcomes — reduces hospital readmissions and enables earlier intervention days before events
- Epic EHR integration — fits natively into existing health system infrastructure without workflow disruption
- Merged with CopilotIQ (Oct 2024) — expanded to end-to-end AI in-home care across all care stages
- Hospital@Home validated program — one of few platforms with proven acute-care-at-home deployment at scale
Cons
- Enterprise-only pricing — no self-service or SMB option
- Implementation complexity — requires EHR integration and clinical workflow setup
- No public pricing — evaluation requires direct sales engagement
- Life sciences division divested to ActiGraph (Jan 2025)
- Primarily US-focused deployment despite global presence
- Not available to individual clinicians or small practices